Injection frequency of Fulvestrant/Fuxit and how long to take an injection

Fulvestrant is an intramuscular injection drug mainly used to treat hormone receptor-positive breast cancer, especially those patients who are resistant to endocrine therapy. The drug enters the human body directly through injection and quickly exerts its effect to control the growth of cancer cells. The frequency and method of injection of Fulvestrant play a crucial role in the efficacy of the drug, so it is important for patients to understand its injection method and schedule.

Treatment with fulvestrant is usually intensive at the beginning of treatment, and then gradually transitions to maintenance treatment. Specifically, patients need to receive injections on Day 1, Day 15 and Day 29 of treatment. This is because the initial treatment of fulvestrant aims to quickly control tumor growth through frequent drug administration and to achieve the effect of effectively inhibiting hormone receptor-positive tumors through high concentrations of the drug.

Beginning on day 29, the frequency of treatment will be reduced to one injection per month. Thereafter, patients will receive an injection at a fixed time every month to maintain the drug concentration in the body and continue the therapeutic effect. The dose of each injection is 500mg, and each injection contains 250mg/5ml. Therefore, each treatment needs to be divided into two injections, injected into the patient's left and right buttocks respectively, and one injection (250mg/5ml) is injected into each buttock. When injecting, the nurse will ensure that each injection is injected slowly, and each injection takes about 1 to 2 minutes. This can minimize discomfort and ensure the smooth entry of the drug into the muscle.

Throughout the treatment process, the patient's injection site requires special attention. If you experience redness, swelling, pain or other discomfort at the injection site, you should report it to your doctor promptly. Typically, mild discomfort at the injection site is normal, but if symptoms persist or worsen, treatment options may need to be reevaluated.

Reference materials:https://medlineplus.gov/druginfo/meds/a607031.html